PMID- 27605053
OWN - NLM
STAT- MEDLINE
DCOM- 20170215
LR  - 20181113
IS  - 1432-2307 (Electronic)
IS  - 0945-6317 (Linking)
VI  - 469
IP  - 6
DP  - 2016 Dec
TI  - Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are 
      associated with deletion of PARP1 and 13q14.
PG  - 697-706
AB  - Leukemic non-nodal mantle cell lymphoma (lMCL) is a particular subtype of mantle 
      cell lymphoma (MCL), characterized by leukemic non-nodal disease and slow 
      progression. Recognition of this entity is relevant to avoid overtreatment. 
      Despite indolent clinical behaviour, lMCL might transform to a more aggressive 
      disease. The purpose of this study was to compare lMCL with classical MCL (cMCL) 
      and aggressive MCL (aMCL) using immunohistochemistry, interphase fluorescence in 
      situ hybridization (FISH), and array-based comparative genomic hybridization, in 
      order to identify biomarkers for lMCL diagnosis and prognosis. Seven lMCL 
      patients were included. All had bone marrow involvement without lymphadenopathy. 
      An lMCL phenotype was distinct from that of cMCL and aMCL: SOX11-, ATM+, 
      PARP1+/-, and low KI67 (average 2 %). Beyond the t(11;14) translocation, fewer 
      secondary cytogenetic alterations were found in lMCL compared to cMCL and aMCL, 
      including deletion of PARP1 and 13q14. At last follow-up, one patient with lMCL 
      had died of disease and another had progressive disease. These patients were 
      respectively 13q14 deletion- and PARP1-positive. One other case of lMCL harbored 
      a 13q14 deletion associated with PARP1 deletion. This patient had indolent 
      disease. lMCL has a particular phenotype and fewer secondary cytogenetic 
      alterations than cMCL and aMCL. PARP1 protein expression and 13q14 deletion are 
      associated with a progressive clinical course of lMCL and should be included in 
      initial diagnostic studies as predictors of unfavorable outcome. PARP1 deletion 
      is involved in lMCL pathogenesis and might confer advantage.
FAU - Gallo, Mathieu
AU  - Gallo M
AD  - Departement de Biopathologie, Hopital Gui De Chauliac, CHU Montpellier, 34275, 
      Montpellier, France.
AD  - Faculte de Medecine, Universite Montpellier, 2 rue ecole de Medecine, 34060, 
      Montpellier, France.
FAU - Cacheux, Valere
AU  - Cacheux V
AD  - Departement d'Hematologie biologique, Hopital Saint Eloi, CHU Montpellier, 34275, 
      Montpellier, France.
AD  - Faculte de Medecine, Universite Montpellier, 2 rue ecole de Medecine, 34060, 
      Montpellier, France.
FAU - Vincent, Laure
AU  - Vincent L
AD  - Departement d'Hematologie clinique, Hopital Saint Eloi, CHU Montpellier, 34275, 
      Montpellier, France.
AD  - Faculte de Medecine, Universite Montpellier, 2 rue ecole de Medecine, 34060, 
      Montpellier, France.
FAU - Bret, Caroline
AU  - Bret C
AD  - Departement d'Hematologie biologique, Hopital Saint Eloi, CHU Montpellier, 34275, 
      Montpellier, France.
AD  - Faculte de Medecine, Universite Montpellier, 2 rue ecole de Medecine, 34060, 
      Montpellier, France.
FAU - Tempier, Ariane
AU  - Tempier A
AD  - Departement de Biopathologie, Hopital Gui De Chauliac, CHU Montpellier, 34275, 
      Montpellier, France.
FAU - Guittard, Caroline
AU  - Guittard C
AD  - Departement d'Hematologie biologique, Hopital Saint Eloi, CHU Montpellier, 34275, 
      Montpellier, France.
FAU - Mace, Alexandra
AU  - Mace A
AD  - Departement d'Hematologie biologique, Hopital Saint Eloi, CHU Montpellier, 34275, 
      Montpellier, France.
FAU - Leventoux, Nicolas
AU  - Leventoux N
AD  - Departement de Biopathologie, Hopital Gui De Chauliac, CHU Montpellier, 34275, 
      Montpellier, France.
FAU - Costes, Valerie
AU  - Costes V
AD  - Departement de Biopathologie, Hopital Gui De Chauliac, CHU Montpellier, 34275, 
      Montpellier, France.
AD  - Faculte de Medecine, Universite Montpellier, 2 rue ecole de Medecine, 34060, 
      Montpellier, France.
FAU - Szablewski, Vanessa
AU  - Szablewski V
AD  - Departement de Biopathologie, Hopital Gui De Chauliac, CHU Montpellier, 34275, 
      Montpellier, France. vszmed@hotmail.fr.
AD  - Faculte de Medecine, Universite Montpellier, 2 rue ecole de Medecine, 34060, 
      Montpellier, France. vszmed@hotmail.fr.
AD  - Departement de Biopathologie Cellulaire et Tissulaire des Tumeurs, Hopital Gui De 
      Chauliac, CHU Montpellier, 34275, Montpellier, France. vszmed@hotmail.fr.
LA  - eng
PT  - Journal Article
DEP - 20160907
PL  - Germany
TA  - Virchows Arch
JT  - Virchows Archiv : an international journal of pathology
JID - 9423843
RN  - EC 2.4.2.30 (PARP1 protein, human)
RN  - EC 2.4.2.30 (Poly (ADP-Ribose) Polymerase-1)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Chromosome Deletion
MH  - *Chromosomes, Human, Pair 13
MH  - Comparative Genomic Hybridization/methods
MH  - Female
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Lymphoma, Mantle-Cell/*diagnosis/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Phenotype
MH  - Poly (ADP-Ribose) Polymerase-1/*genetics
MH  - Prognosis
MH  - Translocation, Genetic/*genetics
OTO - NOTNLM
OT  - Cytogenetic
OT  - Indolent
OT  - Mantle cell lymphoma
OT  - PARP1
EDAT- 2016/09/09 06:00
MHDA- 2017/02/16 06:00
CRDT- 2016/09/09 06:00
PHST- 2016/05/31 00:00 [received]
PHST- 2016/08/30 00:00 [accepted]
PHST- 2016/07/22 00:00 [revised]
PHST- 2016/09/09 06:00 [pubmed]
PHST- 2017/02/16 06:00 [medline]
PHST- 2016/09/09 06:00 [entrez]
AID - 10.1007/s00428-016-2016-8 [pii]
AID - 10.1007/s00428-016-2016-8 [doi]
PST - ppublish
SO  - Virchows Arch. 2016 Dec;469(6):697-706. doi: 10.1007/s00428-016-2016-8. Epub 2016 
      Sep 7.